Octreotide, 30 mg i.m. LAR formulation
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Proliferative Diabetic Retinopathy
Conditions
Proliferative Diabetic Retinopathy
Trial Timeline
Dec 1, 2003 → —
NCT ID
NCT00170742About Octreotide, 30 mg i.m. LAR formulation
Octreotide, 30 mg i.m. LAR formulation is a phase 3 stage product being developed by Novartis for Proliferative Diabetic Retinopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT00170742. Target conditions include Proliferative Diabetic Retinopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00170742 | Phase 3 | Terminated |
Competing Products
20 competing products in Proliferative Diabetic Retinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Navitoclax + Ruxolitinib + Celecoxib | AbbVie | Phase 1 | 33 |
| Epcoritamab | AbbVie | Phase 1 | 33 |
| Brolucizumab 6 mg | Novartis | Phase 3 | 77 |
| CANAKINUMAB (ILARIS®) | Novartis | Phase 1 | 33 |
| Lucentis | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Ranibizumab 0.5 mg | Novartis | Phase 2 | 52 |
| AUY922 | Novartis | Phase 2 | 52 |
| Lucentis | Roche | Pre-clinical | 23 |
| Macugen (pegaptanib) + Macugen (Pegaptanib) | Pfizer | Pre-clinical | 22 |
| Macugen ® (pegaptanib sodium) | Pfizer | Approved | 84 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 51 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 2 | 51 |
| VAC85135 + Ipilimumab | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg | Bristol Myers Squibb | Phase 1 | 32 |
| Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 51 |
| 2-mg Intravitreous Aflibercept Injection | Regeneron Pharmaceuticals | Phase 2/3 | 64 |